INS and diabetes mellitus: In addition, according to observational and experimental data, DPP4 inhibitors [10, 11], sulfonylureas [11, 52], and insulin [53], are unlikely to slow cognitive decline beyond the benefits of glycemic control in diabetes without dementia.